Table 1 Characteristics of studies included in the meta-analysis
Author, year | Country | No. of participants | Follow-up (year) | No. of remaining | Comorbidities remission (without medication) | Study type | ||
|---|---|---|---|---|---|---|---|---|
LSG | LRYGB | LSG | LRYGB | |||||
Abbatini, 2010 | Italy | 20 | 16 | 3 | 20 | 16 | FPG < 126 mg/dl, HbA1c < 6.5% | Retrospective |
Ahmed, 2018 | USA | 59 | 57 | 7 | 27 | 26 | NA | Prospective |
Alexandrou, 2014 | Greece | 40 | 55 | 4 | 40 | 55 | NA | Prospective |
Dakour Aridi, 2018 | Lebanon | 400 | 175 | 5 | 87 | 118 | NA | Retrospective |
Boza, 2012 | Chile | 811 | 786 | 3 | 811 | 786 | FPG < 126 mg/dl, HbA1c < 6.5% | Retrospective |
Carandina, 2014 | France | 34 | 74 | 4 | 34 | 74 | NA | Retrospective |
Dogan, 2015 | Netherlands | 255 | 430 | 5 | 245 | 245 | NA | Retrospective |
Du, 2016 | China | 63 | 63 | 3 | 60 | 59 | FPG < 5.6 mmol/l, HbA1c < 6%/BP < 120/80 mmHg | Retrospective |
Climent, 2018 | Spain | 48 | 103 | 5 | 48 | 103 | NA | Retrospective |
Gonzalez-Heredia, 2016 | USA | 77 | 12 | 3 | 30 | 8 | NA | Retrospective |
Ignat, 2017 | France | 55 | 45 | 5 | 41 | 32 | NA | RCT |
Jammu, 2016 | India | 339 | 295 | 5 | 97 | 143 | NA | Prospective |
Jimenez, 2012 | Spain | 55 | 98 | 3 | 55 | 98 | FPG < 126 mg/dl, HbA1c < 6.5% for at least 1 year | Prospective |
Kim, 2019 | Singapore | 256 | 39 | 3 | 71 | 10 | NA | Retrospective |
Kaseja, 2014 | Poland | 33 | 41 | 3 | 33 | 41 | NA | Prospective |
Lager, 2018 | USA | 334 | 380 | 4 | 226 | 272 | HbA1c < 6.5%/BP < 120/80 mmHg | Retrospective |
Lee, 2015 | China | 519 | 519 | 5 | 116 | 218 | NA | Retrospective |
Leyba, 2014 | Venezuela | 42 | 75 | 5 | 27 | 47 | HbA1c < 6% | Prospective |
Perrone, 2017 | Italy | 162 | 142 | 5 | 162 | 142 | NA | Retrospective |
Peterli, 2018 | Switzerland | 112 | 113 | 5 | 101 | 104 | FPG < 100 mg/dl, HbA1c < 6.0% at least 1 year | RCT |
Rondelli, 2017 | Italy | 280 | 301 | 3 | 259 | 282 | NA | Retrospective |
Ruiz-Tovar, 2019 | Spain | 200 | 200 | 5 | 182 | 184 | FPG < 110 mg/dl, HbA1c < 6.5%/BP < 135/85 mmHg/FPT < 200 mg/dl, TC < 200 mg/dl, HDL > 40 mg/dl | RCT |
Salminen, 2018 | Finland | 121 | 119 | 5 | 98 | 95 | FPG < 100 mg/dl, HbA1c < 6.0%/LDL < 115.8 mg/dl | RCT |
Sepulveda, 2018 | Chile | 57 | 55 | 3 | 41 | 35 | FPG < 100 mg/dl, HbA1c < 6.0% | Retrospective |
Vidal, 2013 | Spain | 114 | 135 | 4 | 91 | 108 | NA | Retrospective |
Yang, 2015 | China | 32 | 32 | 3 | 28 | 27 | HbA1c < 6.0% | RCT |
Zhang, 2014 | China | 32 | 32 | 5 | 26 | 28 | NA | RCT |
Schauer, 2017 | USA | 47 | 49 | 5 | 47 | 49 | HbA1c < 6.5% | RCT |